FrancophonIA/ELRC3.0 huggingface dataset:
English: If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) or DRESS (e.g. rash, fever, eosinophilia and systemic involvement (e.g. adenopathy, hepatitis, interstitial nephropathy, interstitial lung disease) are present, PROTELOS treatment should be discontinued immediately.
Croatian: Ukoliko su prisutni simptomi ili znakovi SJS ili TEN (npr. progresivni kožni osip s mjehurićima ili mukoznim lezijama) ili DRESS (npr. osip, vrućica, eozinofilija i sustavni simptomi (npr. adenopatija, hepatitis, intersticijska nefropatija, intersticijska bolest pluća) treba odmah prekinuti primjenu PROTELOS-a.
English: If you take antacids (medicines to relieve heartburn) you should take them at least 2 hours after PROTELOS.
Croatian: Uzimate li antacide (lijekovi protiv žgaravice), smijete ih uzeti tek nakon što prođu najmanje dva sata od uzimanja PROTELOS-a.
English: It is therefore preferable to take antacids at least two hours after PROTELOS.
Croatian: Stoga antacide treba, po mogućnosti, uzimati najmanje dva sata nakon PROTELOS-a.
English: PROTELOS reduced the relative risk of new vertebral fracture by 41% over 3 years in the SOTI study (table 1).
Croatian: PROTELOS je u ispitivanju SOTI tijekom 3 godine smanjio relativni rizik od novog prijeloma kralješnice za 41 % (Tablica 1).
English: PROTELOS also decreased the number of patients with a body height loss of at least 1 cm as compared to placebo.
Croatian: PROTELOS je, u usporedbi s placebom, smanjio i broj bolesnica čija se visina tijela smanjila za više od 1 cm.
English: In pooled randomised placebo-controlled studies of post-menopausal osteoporotic patients, a significant increase in myocardial infarction has been observed in PROTELOS treated patients compared to placebo (see section 4.8).
Croatian: Iz zbirnih podataka iz randomiziranih placebom kontroliranih ispitivanja bolesnika s osteoporozom u postmenopauzi primijećen je značajan porast infarkta miokarda kod bolesnika liječenih PROTELOSom u usporedbi s placebom (vidjeti dio 4.8).
English: Efficacy of PROTELOS to reduce the risk of new vertebral fracture was confirmed in the TROPOS study, including for osteoporotic patients without fragility fracture at baseline.
Croatian: Ispitivanjem TROPOS potvrđena je djelotvornost PROTELOS-a u smanjenju rizika od novih prijeloma kralješnice, uključujući i za bolesnice s osteoporozom bez prijeloma zbog krhkosti kosti na početku ispitivanja.
English: As divalent cations can form complexes with oral tetracycline (e.g. doxycycline) and quinolone antibiotics (e.g. ciprofloxacin) at the gastro-intestinal level and thereby reduce their absorption,
Croatian: Budući da dvovalentni kationi mogu stvarati komplekse s peroralno uzetim tetraciklinskim (npr. doksiciklin) i kinolonskim (npr. ciprofloksacin) antibioticima na gastrointestinalnoj razini i time smanjiti njihovu apsorpciju, ne preporučuje se istodobna primjena stroncijeva ranelata i tih lijekova.
English: o If symptoms or signs of Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) or Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) (e.g. rash, fever, eosinophilia and systemic involvement, e.g. adenopathy, hepatitis, interstitial nephropathy, interstitial lung disease) are present, PROTELOS treatment should be discontinued immediately.
Croatian: o Ukoliko su prisutni simptomi ili znakovi Stevens-Johnsonova sindroma (SJS), toksične epidermalne nekrolize (TEN) ili osipa uzrokovanog lijekom uz eozinofiliju i sustavne simptome (DRESS) (npr. osip, vrućica, eozinofilija i sustavni simptomi npr. adenopatija, hepatitis, intersticijska nefropatija, intersticijska bolest pluća), treba odmah prekinuti primjenu PROTELOS-a.
English: In the absence of bone safety data in patients with severe renal impairment treated with strontium ranelate, PROTELOS is not recommended in patients with a creatinine clearance below 30 ml/min (see section 5.2).
Croatian: Budući da nema podataka o sigurnosti terapije stroncijevim ranelatom s obzirom na utjecaj na koštano tkivo u osoba s teško oštećenom funkcijom bubrega, PROTELOS se ne preporučuje u bolesnika s klirensom kreatinina manjim od 30 ml/min (vidjeti dio 5.2).
English: In an a-posteriori analysis of patients from the pooled SOTI and TROPOS studies with baseline lumbar spine and / or femoral neck BMD in the osteopenic range and without prevalent fracture but with at least one additional risk factor for fracture (N=176), PROTELOS reduced the risk of a first vertebral fracture by 72% over 3 years (incidence of vertebral fracture 3.6% with strontium ranelate vs. 12.0% with placebo).
Croatian: Združena a posteriori analiza podataka iz ispitivanja SOTI i TROPOS o bolesnicama čija je BMD lumbalne kralješnice i/ili vrata bedrene kosti na početku ispitivanja bila u rasponu osteopenije, bez prisutnosti prijeloma, no s najmanje jednim dodatnim čimbenikom rizika za prijelom (N = 176), pokazala je da je PROTELOS tijekom 3 godine smanjio rizik od prvog prijeloma kralješnice za 72 % (incidencija prijeloma kralješnice 3,6 % u skupini koja je uzimala stroncijev ranelat naspram 12,0 % u skupini koja je uzimala placebo).
English: 6.3 Shelf life - 3 years.
Croatian: 6.3 Rok valjanosti
English: In patients over 80 years of age at inclusion, a pooled analysis of SOTI and TROPOS studies showed that PROTELOS reduced the relative risk of experiencing new vertebral fractures by 32% over 3 years (incidence of 19.1% with strontium ranelate vs. 26.5% with placebo).
Croatian: Združena analiza podataka iz ispitivanja SOTI i TROPOS u bolesnica starijih od 80 godina pri uključivanju u ispitivanje, pokazala je da je PROTELOS tijekom 3 godine smanjio relativni rizik od novih prijeloma kralješnice za 32 % (incidencija prijeloma 19,1 % u skupini koja je uzimala stroncijev ranelat naspram 26,5 % u skupini koja je uzimala placebo).
English: Driving and using machines: Protelos is unlikely to affect your ability to drive or use machines.
Croatian: Nije vjerojatno da će PROTELOS utjecati na Vašu sposobnost upravljanja motornim vozilima i strojevima.
English: Pyrexia (in association with hypersensitivity skin reactions)
Croatian: Pireksija (povezano s kožnim reakcijama preosjetljivosti)
English: Package leaflet: Information for the patient PROTELOS 2 g granules for oral suspension Strontium ranelate
Croatian: Uputa o lijeku: Informacija za bolesnika PROTELOS 2 g granule za oralnu suspenziju stroncijev ranelat
English: How PROTELOS works
Croatian: Kako djeluje PROTELOS
English: INFORMATION IN BRAILLE
Croatian: 16. PODACI NA BRAILLEOVOM PISMU PROTELOS
English: If the patient has developed SJS, TEN or DRESS with the use of PROTELOS, PROTELOS must not be re-started in this patient at any time.
Croatian: Ukoliko je bolesnik razvio SJS, TEN ili DRESS za vrijeme primjene PROTELOS-a, kod takvog bolesnika se nikad ne smije ponovno započeti liječenje s PROTELOS-om.
English: If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis or DRESS with the use of PROTELOS, you must not be re-started on PROTELOS at any time If you are of Asian origin, you may be at higher risk of skin reactions.
Croatian: Ukoliko ste razvili simptome Stevens-Johnson-ov sindroma ili toksične epidermalne nekrolize ili DRESS-a tijekom primjene PROTELOS-a, ne smijete nikad više ponovo započeti liječenje PROTELOS-om.
English: Where possible, screening for HLA-A*33:03 and HLA-B*58:01 alleles could be considered before starting treatment with PROTELOS in patients of Han Chinese origin.
Croatian: Kada je to moguće, prije započinjanja liječenja PROTELOS-om u bolesnika Han kineskog podrijetla, može se razmotriti probir na alele HLAA*33:03 i HLA-B*58:01.
English: Strontium ranelate is not recommended for patients with severe renal impairment (creatinine clearance below 30 ml/min) (see sections 4.4 and 5.2).No dose adjustment is required in patients with mild-to-moderate renal impairment (30-70 ml/min creatinine clearance) (see sections 4.4 and 5.2).
Croatian: Stroncijev se ranelat ne preporučuje bolesnicima s teško oštećenom funkcijom bubrega (klirens kreatinina manji od 30 ml/min) (vidjeti dijelove 4.4 i 5.2).
English: NAME OF THE MEDICINAL PRODUCT PROTELOS 2 g granules for oral suspension
Croatian: NAZIV LIJEKA PROTELOS 2 g granule za oralnu suspenziju
English: An a-posteriori analysis was performed on a subgroup of patients from the TROPOS study of particular medical interest and at high-risk of fracture [defined by a femoral neck BMD T-score ≤3 SD (manufacturer's range corresponding to -2.4 SD using NHANES III) and an age ≥ 74 years (n=1,977, i.e. 40% of the TROPOS study population)].
Croatian: BMD vrata bedrene kosti ≤ -3 SD (raspon proizvođača lijeka, jednak je rasponu od -2,4 SD prema ljestvici NHANES III) i dobi ≥ 74 godine (n=1977, tj. oko 40 % populacije uključene u istraživanje TROPOS)].
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/288/004 56 sachets
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/04/288/004 56 vrećica
English: Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis and severe hypersensitivity reactions (DRESS)) have been reported with the use of PROTELOS.
Croatian: Tijekom uzimanja PROTELOS-a prijavljena je pojava moguće po život opasnih osipa na koži (Stevens-Johnson-ov sindrom, toksična epidermalna nekroliza i teške reakcije preosjetljivosti (DRESS)).
English: Life-threatening cutaneous reactions (Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS)) have been reported with the use of PROTELOS.
Croatian: Pri primjeni PROTELOS-a zabilježeni su slučajevi po život opasnih kožnih reakcija (StevensJohnsonov sindrom (SJS), toksična epidermalna nekroliza (TEN) i osip uzrokovan lijekom uz eozinofiliju i sustavne simptome (DRESS).
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION PROTELOS 2 g granules for oral suspension.
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA PROTELOS 2 g granule za oralnu suspenziju stroncijev ranelat.
English: Maltodextrin
Croatian: Papaellinas Ltd.
English: st year
Croatian: - 3 godine.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/288/002
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/04/288/002
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/288/001
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/04/288/001
English: Excipient
Croatian: Ekcem
English: NAME OF THE MEDICINAL PRODUCT PROTELOS 2 g granules for oral suspension Strontium ranelate
Croatian: PROTELOS 2 g granule za oralnu suspenziju stroncijev ranelat
English: Mannitol (E421)
Croatian: 6.1 Popis pomoćnih tvari aspartam (E951) maltodekstrin manitol (E421)
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/288/003
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/04/288/003
English: Luxembourg/Luxemburg S.A. Servier Benelux N.V. Tel: +32 (0)2 529 43 11
Croatian: Slovenská republika Servier Slovensko spol. s r.o. Tel.:+421 (0)2 5920 41 11
English: PROTELOS is contra-indicated in patients with a past history of venous thromboembolic events (see section 4.3) and should be used with caution in patients at risk of VTE.
Croatian: VTE u anamnezi (vidjeti dio 4.3), a mora se primjenjivati s oprezom u osoba s povećanim rizikom od VTE.
English: This leaflet was last approved in 12/2016.
Croatian: Ova uputa je zadnji puta revidirana u 12/2016.
English: The frequency of the type of event is not known (cannot be estimated from available data).
Croatian: Učestalost te vrste događaja nije poznata (ne može se procijeniti iz dostupnih podataka).
English: Recommended distance from target tissue
Croatian: Preporučena udaljenost od ciljnog tkiva
English: 1.5 Bar (22 psi)
Croatian: 1,5 Bara (22 psi)
English: Maximum amount of Raplixa recommended is 3 gram.
Croatian: Maksimalna količina lijeka Raplixa koja se preporučuje je 3 grama.
English: The following is intended for healthcare professionals only:
Croatian: Sljedeće informacije namijenjene su samo zdravstvenim djelatnicima:
English: Elderly Dose adjustment not required.
Croatian: Starije osobe Prilagodba doze nije potrebna.
English: Higher dosages up to 4g (including re-application and treatment of more than a single bleeding site) may be needed.
Croatian: Mogu biti potrebne veće doze do 4 g (uključujući i ponovnu primjenu i liječenje više od jednog mjesta krvarenja).
English: If these symptoms occur, the administration should be discontinued immediately.
Croatian: Ako se pojave ti simptomi, primjena se mora odmah prekinuti.
English: Fibrin sealants may, in rare cases (up to 1 in 1,000 people), cause an allergic reaction.
Croatian: Fibrinska tkivna ljepila mogu, u rijetkim slučajevima (u do 1 na 1000 osoba), uzrokovati alergijsku reakciju.
English: In case of shock, standard medical treatment for shock should be implemented.
Croatian: U slučaju šoka, mora se provesti standardno medicinsko liječenje šoka.
English: What Raplixa is and what it is used for
Croatian: Što je Raplixa i za što se koristi
English: • Use preferred pressurised CO2 instead of pressurised air
Croatian: • Uporabi najprikladnijeg stlačenog CO2 umjesto stlačenog zraka
English: The application can be repeated, if necessary.
Croatian: Primjena se može ponoviti prema potrebi.
English: Raplixa is indicated in adults over 18 years of age.
Croatian: Raplixa je indiciran u odraslih starijih od 18 godina.
English: Human plasma
Croatian: Ljudska plazma
English: • Use of the correct pressure (not exceed 1.5 bars or 22 psi) and distance from tissue not closer than
Croatian: • Uporabi pravilnog tlaka (ne smije premašiti 1,5 bara ili 22 psi) i udaljenosti od tkiva ne bliže od
English: 35041 Marburg (Stadtteil Michelbach) Germany
Croatian: 35041 Marburg (Stadtteil Michelbach) Njemačka
English: Martin House, Gloucester Crescent, Wigston, Leicester, Leicestershire, LE18 4YL, United Kingdom
Croatian: Martin House, Gloucester Crescent, Wigston, Leicester, Leicestershire, LE18 4YL, Ujedinjeno Kraljevstvo
English: Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.
Croatian: Neklinički podaci nisu ukazali na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza i genotoksičnosti.
English: The Guide for healthcare professionals shall inform on the following key elements:
Croatian: Upute za zdravstvene djelatnike moraju sadržavati informacije o sljedećim ključnim elementima:
English: Spray distance from tissue and pressure should be within the ranges recommended by the manufacturer (see table in section 6.6 for pressure and distance).
Croatian: Udaljenost raspršivanja od tkiva i tlak trebaju biti u rasponima koje preporučuje proizvođač (vidjeti tablicu u dijelu 6.6 za tlak i udaljenost).
English: Do not use Raplixa for treatment of severe arterial bleeding.
Croatian: Nemojte koristiti lijek Raplixa za liječenje teškog arterijskog krvarenja.
English: Keep the vial in the outer packaging in order to protect from light.
Croatian: Bočicu čuvati u vanjskom pakiranju radi zaštite od svjetlosti.
English: Do not use Raplixa (and gelatin sponge) in contaminated areas of the body, or in the presence of active infection.
Croatian: Nemojte koristiti lijek Raplixa (ni želatinsku spužvicu) u kontaminiranim područjima tijela, ili u prisustvu aktivne infekcije.
English: Human Fibrinogen
Croatian: Ljudski fibrinogen
English: Such substances should be removed as much as possible before applying the product.
Croatian: Takve tvari bi trebalo što više ukloniti prije primjene lijeka.
English: No formal interaction studies have been performed.
Croatian: Formalna ispitivanja interakcija nisu provedena.
English: As with any protein product, allergic type hypersensitivity reactions are possible.
Croatian: Kao i kod bilo kojeg proteinskog lijeka, moguće su reakcije preosjetljivosti alergijskog tipa.
English: The following side effects have also been reported: Common side effects (may affect up to 1 in 10 people):
Croatian: Sljedeće nuspojave su također prijavljene: Česte nuspojave (mogu se pojaviti u 1 na 10 osoba):
English: The fibrin adhesion system initiates the last phase of physiological blood coagulation.
Croatian: Sustav fibrinskog prianjanja započinje zadnju fazu fiziološkog zgrušavanja krvi.
English: Name and address of the manufacturers of the biological active substances CSL Behring GmbH
Croatian: Nazivi i adrese proizvođača bioloških djelatnih tvari CSL Behring GmbH
English: Conventional surgical techniques such as suture, ligature and cautery were ineffective or impractical.
Croatian: Konvencionalne kirurške tehnike, primjerice šivanje, podvezivanje (ligiranje) i kauterizacija bile su neučinkovite ili nepraktične.
English: Raplixa may also be used with medical air (see sections 4.4 and 6.6).
Croatian: Raplixa se također može koristiti i s medicinskim zrakom (vidjeti dijelove 4.4 i 6.6).
English: The safety of Raplixa for use in human pregnancy or during breast-feeding has not been established in controlled clinical trials.
Croatian: Sigurnost lijeka Raplixa za uporabu u ljudskoj trudnoći ili tijekom dojenja nije utvrđena u kontroliranim kliničkim ispitivanjima.
English: Transmissible infectious agents
Croatian: Prenosivi infektivni agensi
English: In the event of overdose, patients must be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment and supportive measures instituted.
Croatian: U slučaju predoziranja, bolesnici trebaju biti pomno praćeni zbog znakova ili simptoma nuspojava te se moraju primijeniti odgovarajuće simptomatsko liječenje i suportivne mjere.
English: Raplixa should not be sprayed at a distance closer than that recommended by the spray device manufacturer and in no case closer than 5 cm from the tissue surface.
Croatian: Raplixa se ne smije raspršivati na udaljenosti manjoj od one koju preporučuje proizvođač raspršivača i ni u kojem slučaju bliže od 5 cm od površine tkiva.
English: Raplixa may also be used with medical air.
Croatian: Raplixa se također može koristiti i s medicinskim zrakom.
English: It is called an air or gas embolism.
Croatian: To se zove zračna ili plinska embolija.
English: Such reactions may especially be seen, if the preparation is applied repeatedly, or administered to patients known to be hypersensitive to constituents of the product.
Croatian: Takve reakcije se mogu osobito uočiti ako se pripravak primjenjuje u više navrata, ili se daje bolesnicima za koje je poznato da su preosjetljivi na sastojke lijeka.
English: The MAH shall ensure that in each Member State where Raplixa is marketed, all healthcare professionals who are expected to use Raplixa are provided with the following educational material:
Croatian: Nositelj odobrenja će osigurati da, u svim državama članicama gdje je lijek Raplixa u prometu, svi zdravstveni djelatnici od kojih se očekuje da će koristiti lijek Raplixa dobiju sljedeći edukacijski materijal:
English: Store between + 2 °C to + 25 °C.
Croatian: Čuvati na temperaturi od + 2 °C do + 25 °C.
English: There is not enough information available to know whether any particular risks are associated with the use of Raplixa during pregnancy or whilst breast-feeding.
Croatian: Nema dovoljno dostupnih informacija o tome jesu li određeni rizici povezani s uzimanjem lijeka Raplixa tijekom trudnoće ili tijekom dojenja.
English: Supportive treatment where standard surgical techniques are insufficient for improvement of haemostasis.
Croatian: Suportivno liječenje kada su standardne kirurške tehnike nedovoljne za poboljšanje hemostaze.
English: Before administration of Raplixa care is to be taken that parts of the body outside the desired application area are sufficiently protected (covered) to prevent tissue adhesion at undesired sites.
Croatian: Prije primjene lijeka Raplixa nužno je paziti da su dijelovi tijela izvan željenog područja primjene dovoljno zaštićeni (pokriveni) kako bi se spriječila adhezija tkiva na neželjenim mjestima.
English: Excessive clot thickness may negatively interfere with the product's efficacy and the wound healing process.
Croatian: Pretjerana debljina ugruška može negativno utjecati na djelotvornost lijeka i proces zacjeljivanja rane.
English: Air or gas emboli
Croatian: Zračna ili plinska embolija
English: Clinical studies in the EU were done with the CE marked Spongostan gelatin sponge.
Croatian: Klinička ispitivanja u EU provedena su želatinskom spužvicom Spongostan s oznakom CE.
English: For safety with respect to transmissible agents, see section 4.4.
Croatian: Za sigurnost vezanu uz prenosive agense, vidjeti dio 4.4.
English: • Nearby areas should be protected to make sure that Raplixa is only applied onto the surface which is to be treated.
Croatian: • Obližnja područja moraju biti zaštićena da bi se osigurala primjena lijeka Raplixa samo na površinu koju treba liječiti.
English: Other medicines and Raplixa Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Croatian: Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove.
English: In absence of compatibility studies, Raplixa must not be mixed with other medicinal products.
Croatian: Zbog nedostatka ispitivanja kompatibilnosti, Raplixa se ne smije miješati s drugim lijekovima.
English: The pressure should be within the range recommended by ProFibrix.
Croatian: Tlak mora biti unutar raspona koji preporučuje ProFibrix.
English: There is also a possibility that you could develop antibodies to the proteins in Raplixa, which could potentially interfere with blood clotting.
Croatian: Postoji i mogućnost da biste mogli razviti protutijela na proteine u lijeku Raplixa, što potencijalno može ometati zgrušavanje krvi.
English: In clinical trials, smaller bleeding sites (< 10 cm²) used 0.5 g to 1 g on average.
Croatian: U kliničkim ispitivanjima, za manja mjesta krvarenja (<10 cm²) prosječno se koristi od 0,5 g do 1 g.
English: Larger bleeding sites used 1 to 2 grams (10-100 cm²).
Croatian: Za veća mjesta krvarenja koristi se od 1 do 2 grama (10-100 cm²).
English: The dose to be applied is governed by variables including, but not limited to, the type of surgery, the size of the bleeding surface area, the severity of bleeding, the mode of application selected by the surgeon, and the number of applications.
Croatian: Doza koja će se primijeniti određena je varijablama, uključujući, ali ne ograničavajući se na tip kirurškog zahvata, veličinu površine krvarenja, jačinu krvarenja, način primjene odabran od strane kirurga i broj primjena.
English: Prior to launch of Raplixa in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.
Croatian: Prije početka prodaje lijeka Raplixa u državi članici, nositelj odobrenja mora dogovoriti s nadležnim državnim tijelom sadržaj i oblik edukacijskog programa, uključujući komunikacijske medije, načine distribucije i sve ostale osobine programa.
English: This also applies to unknown or emerging viruses and other pathogens.
Croatian: To se također odnosi na nepoznate ili novonastale viruse i ostale patogene.
English: 1 vial 0.5 g 1 vial 1 g 1 vial 2 g
Croatian: Prašak tkivnog ljepila 1 bočica 0,5 g 1 bočica 1 g 1 bočica 2 g
English: Factor XIIIa, which is activated from factor XIII by thrombin, crosslinks fibrin.
Croatian: Faktor XIIIa, koji se aktivira iz faktora XIII trombinom, unakrsno povezuje fibrin.
English: What you need to know before you are treated with Raplixa
Croatian: Što morate znati prije nego dobijete lijek Raplixa